AbbVie stock: Higher 2026 outlook follows Q3 revenue growth
Published on 11/03/2026 at 15:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGuidance strengthens after quarterly growth
- Adjusted diluted earnings per share reached USD 3.82 in the third quarter.
- Immunology and neuroscience led portfolio growth, while aesthetics revenue declined.
- AbbVie also announced a higher quarterly dividend beginning in February 2027.
AbbVie raised its adjusted 2026 earnings outlook after third-quarter revenue growth and broad portfolio gains. In its October 30 release on PR Newswire, the drugmaker reported USD 17.404 billion in revenue for the quarter ended September 30, 2026, and lifted its full-year adjusted diluted EPS range to USD 13.95-13.99 from USD 13.76-13.96.
Higher guidance follows broad growth
Adjusted diluted EPS reached USD 3.82, including an unfavorable USD 0.11-per-share impact from acquired research and development and milestone expense. The full-year outlook includes a USD 0.69-per-share impact from those expenses incurred through the first nine months.
Immunology revenue rose to USD 9.165 billion, with Skyrizi revenue at USD 5.776 billion and Rinvoq revenue at USD 2.706 billion. Neuroscience revenue reached USD 3.389 billion. Oncology revenue increased modestly to USD 1.696 billion, while aesthetics revenue declined to USD 1.176 billion.
Portfolio momentum meets execution risks
AbbVie also completed its acquisition of Apogee Therapeutics, adding late-stage and earlier-stage immunology assets. The release highlighted regulatory and clinical progress across immunology, neuroscience and oncology, but the guidance excludes any acquired research and development or milestone expense that may arise after the third quarter.
The company raised its quarterly cash dividend from USD 1.73 to USD 1.82 per share, with the higher payment scheduled for February 16, 2027. The real-time quote of AbbVie stock stood at EUR 259.40 on Lang & Schwarz at 15:36 CET on Tuesday, November 3, 2026.
Compared with the EUR 262.80 quote in the previous own report from November 2, the new quote was 1.29 percent lower. This comparison since the previous report is separate from the Xetra session comparison.
AbbVie Inc. at a glance
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Home exchange: NYSE
- Lang & Schwarz quote: EUR 259.40 on November 3, 2026 at 15:36 CET
- Quarterly adjusted diluted EPS: USD 3.82 for the quarter ended September 30, 2026
- 2026 adjusted diluted EPS outlook: USD 13.95-13.99
- Dividend: USD 1.82 per share from February 2027
- Index membership: S&P Dividend Aristocrats Index
US equities remain the relevant market backdrop for AbbVie stock; investors can follow the S&P 500 market environment.
More news and analyses on AbbVie stock track the company's earnings, pipeline and dividend developments.
